MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors

Bellmunt J, Delgado FM, George C.

Medical Oncology Service, University Hospital Del Mar, Paseo Maritimo 25-29, Barcelona, Spain. jbellmunt@imas.imim.es

Abstract

Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.

Both comments and trackbacks are currently closed.